The COMTval 158 met polymorphism is associated with symptom relief during exposure-based cognitive-behavioral treatment in panic disorder
暂无分享,去创建一个
[1] Per Carlbring,et al. Internet-versus group-administered cognitive behaviour therapy for panic disorder in a psychiatric setting: a randomised trial , 2010, BMC psychiatry.
[2] K. Felmingham,et al. Preliminary Evidence of the Short Allele of the Serotonin Transporter Gene Predicting Poor Response to Cognitive Behavior Therapy in Posttraumatic Stress Disorder , 2010, Biological Psychiatry.
[3] Stephan Kolassa,et al. The Risk of Posttraumatic Stress Disorder After Trauma Depends on Traumatic Load and the Catechol-O-Methyltransferase Val158Met Polymorphism , 2010, Biological Psychiatry.
[4] Volker Arolt,et al. COMT val158met influence on electroconvulsive therapy response in major depression , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[5] Alfons O. Hamm,et al. Genetic Gating of Human Fear Learning and Extinction , 2009, Psychological science.
[6] G. Andersson,et al. An open study of the effectiveness of Internet treatment for panic disorder delivered in a psychiatric setting , 2009, Nordic journal of psychiatry.
[7] M. Reger,et al. A meta-analysis of the effects of internet- and computer-based cognitive-behavioral treatments for anxiety. , 2009, Journal of clinical psychology.
[8] T. Lehtimäki,et al. Dopamine 2 receptor C957T and catechol-o-methyltransferase Val158Met polymorphisms are associated with treatment response in electroconvulsive therapy , 2008, Neuroscience Letters.
[9] Britt Klein,et al. Is internet-based CBT for panic disorder and agoraphobia as effective as face-to-face CBT? , 2008, Journal of anxiety disorders.
[10] T. Lehtimäki,et al. Catechol-O-methyltransferase (COMT) polymorphisms predict treatment response in electroconvulsive therapy , 2008, The Pharmacogenomics Journal.
[11] V. Arolt,et al. Association of the COMT val158met Variant with Antidepressant Treatment Response in Major Depression , 2008, Neuropsychopharmacology.
[12] Katharina Domschke,et al. Meta‐analysis of COMT val158met in panic disorder: Ethnic heterogeneity and gender specificity , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[13] M. Davis,et al. Mechanisms of fear extinction , 2007, Molecular Psychiatry.
[14] J. Woo,et al. Tryptophan hydroxylase and serotonin transporter gene polymorphism does not affect the diagnosis, clinical features and treatment outcome of panic disorder in the Korean population , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[15] Fabio Macciardi,et al. Association of the Val158Met Catechol O-Methyltransferase Genetic Polymorphism with Panic Disorder , 2006, Neuropsychopharmacology.
[16] S. Hofmann,et al. Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine. , 2006, CNS drug reviews.
[17] D. Linden,et al. How psychotherapy changes the brain – the contribution of functional neuroimaging , 2006, Molecular Psychiatry.
[18] L. Fañanás,et al. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. , 2006, Journal of affective disorders.
[19] Andreas Heinz,et al. The Effects of Catechol O-methyltransferase Genotype on Brain Activation Elicited by Affective Stimuli and Cognitive Tasks , 2006, Reviews in the neurosciences.
[20] G. Andersson,et al. Treatment of panic disorder: live therapy vs. self-help via the Internet. , 2005, Behaviour research and therapy.
[21] Darin D Dougherty,et al. Neuroimaging and the functional neuroanatomy of psychotherapy , 2005, Psychological Medicine.
[22] R Kohnen,et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression , 2005, The Pharmacogenomics Journal.
[23] G. Sedvall,et al. Dopamine D2-receptor gene polymorphisms in scandinavian chronic alcoholics , 2005, European Archives of Psychiatry and Clinical Neuroscience.
[24] M. Egan,et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. , 2004, American journal of human genetics.
[25] A. Grace,et al. The Catechol-O-Methyltransferase Polymorphism: Relations to the Tonic–Phasic Dopamine Hypothesis and Neuropsychiatric Phenotypes , 2004, Neuropsychopharmacology.
[26] Justine M. Kent,et al. Neuroanatomical Hypothesis of Panic Disorder, Revised , 2004 .
[27] Katharina Domschke,et al. Association of the functional V158M catechol-O-methyl-transferase polymorphism with panic disorder in women. , 2004, The international journal of neuropsychopharmacology.
[28] S. Ho,et al. Human catechol-O-methyltransferase down-regulation by estradiol , 2003, Neuropharmacology.
[29] T. Inada,et al. Relationship between catechol‐O‐methyltransferase polymorphism and treatment‐resistant schizophrenia , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[30] David Goldman,et al. Genetic origins of anxiety in women: a role for a functional catechol-O-methyltransferase polymorphism , 2003, Psychiatric genetics.
[31] T. T. Haug,et al. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. , 2002, Journal of psychosomatic research.
[32] S. Mineka,et al. A modern learning theory perspective on the etiology of panic disorder. , 2001, Psychological review.
[33] E. Kandel,et al. Biology and the future of psychoanalysis: a new intellectual framework for psychiatry revisited. , 1999, The American journal of psychiatry.
[34] T Foitzi,et al. Allelic discrimination using fluorogenic probes and the 5' nuclease assay , 1999 .
[35] R. Weinshilboum,et al. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. , 1999, Annual review of pharmacology and toxicology.
[36] P. Munk-Jørgensen,et al. Acta Psychiatrica Scandinavica , 1998 .
[37] E. Kandel,et al. A new intellectual framework for psychiatry. , 1998, The American journal of psychiatry.
[38] D. Sheehan,et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.
[39] R. Weinshilboum,et al. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. , 1996, Pharmacogenetics.
[40] Gesamtverband Deutscher Nervenärzte. European archives of psychiatry and clinical neuroscience , 1990 .
[41] R. Snaith,et al. The hospital anxiety and depression scale. , 2013, Acta psychiatrica Scandinavica.